博士毕业神器3+分纯生信杂志:平均一审只要一个月,年刊量1000+

Aims and Scope

OncoTargets and Therapy是一本同行评审的国际期刊,专注于针对所有类型癌症的分子诊断以及靶向分子或其他精准治疗。该杂志探讨了新疗法和现有疗法背后的机制,以帮助临床医生更好的理解和治疗肿瘤。

OTT杂志2014-2020年IF的走势

OTT从2014年开始,国人发表量就比较高了,到2018年开始文章就接近1000篇,虽然可能会受到“唯SCI论”的影响,大家对低分SCI的热情不如之前;但是目前看来2020年预计也有1000篇左右国人发表量接近75%,比之前的Aging还要高。


下图可以看到,5年IF也是能接近3分,说明最近5年的文章都是很稳定的,和现在的IF是差不多的水平,加上之前16和17年本来IF都是偏低的,也就是说最近几年的文章质量可能相对之前是有上涨的。


如果在OTT,或者是其他的DovePress的杂志上发表过文章的话,杂志集团会让你加入Favored Author Program,加入这个项目以后你可以获得以下特权:

  • Fast-track processing of papers;

  • Rapid delivery of a PDF of your paper for your personal use;

  • A 10% discount off the article publishing charge.

给大家划个重点!!!快速审稿,快速排版和减免10%的版面费。


接下来就是大家很关心的审稿周期了,大家可以看到,这里写得是从投稿到一审结束只要26天,当然这里其实是指26个工作日,实际也就是平均1个月的自然日就能有一审消息了。并且一般接受到Online平均只要11天的时间。

小编自己的两篇文章一篇用了38天,一篇用了20天就有一审结果了;第二篇可能是因为当时加入了Favored Author Program能快了一些。总体而言,对于那些审稿动不动3-4个月的杂志已经是非常非常快了。

此外,如果以通讯作者在该杂志发表论文了以后,并且同意成为审稿人以后;杂志可能会根据你的前期研究方向加上避免作者利益冲突的情况下,给你发出同行评议邀请;小编从第一篇文章接受了以后到现在2年的时间已经帮DovePress的几个杂志审稿5篇了。

小编还在杂志官网看到OTT的Rejection Rate有73%,也就是说只有1/4多一点的稿子会被接受,这个接受率是已经很低的了,所以我才说OTT很多文章已经接近Frontiers in Oncology的水平了。


 那很多小伙伴更关心的是,OTT对生信杂志怎样呢?笔者阅读了一下,目前OTT在2019和2020年目前截止发表了论文总数有1300+篇,能够归到纯生信的有30篇左右,虽然不算多,但是至少说明OTT对纯生信的文章并不排除。并且笔者发现,纯生信的文章还是和Risk Score免疫浸润为主的分析。

1.An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma


2.Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization


3.Analysis of risk factors for colon cancer progression


4.Assessment of tumor mutation burden calculation from gene panel sequencing data.


5.Clinical Significance And Integrative Analysis Of Kinesin Family Member 18B In Lung Adenocarcinoma


6.Combining data from Tcga and geO databases and reverse transcription quantitative Pcr validation to identify gene prognostic markers in lung cancer


7.Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma


8.Construction of prognostic microRNA signature for human invasive breast cancer by integrated analysis


9.Demethylation and Overexpression of CSF2 are Involved in Immune Response, Chemotherapy Resistance, and Poor Prognosis in Colorectal Cancer


10.Five Hub Genes Can Be The Potential DNA Methylation Biomarkers For Cholangiocarcinoma Using Bioinformatics Analysis


11.Hypermethylated KLF9 Is An Independent Prognostic Factor For Favorable Outcome In Breast Cancer


12.Identification and validation of an individualized autophagy-clinical prognostic index in bladder cancer patients


13.Identification of key genes and pathways in Ewing’s sarcoma patients associated with metastasis and poor prognosis


14.Identification of Novel lncRNA Markers in Glioblastoma Multiforme and Their Clinical Significance- A Study Based on Multiple Sequencing Data


15.Identification of seven-gene signature for prediction of lung squamous cell carcinoma


16.Prognostic Correlation of Autophagy-Related Gene Expression-Based Risk Signature in Patients with Glioblastoma


17.MIR22HG As A Tumor Suppressive lncRNA In HCC- A Comprehensive Analysis Integrating RT-qPCR, mRNA-Seq, And Microarrays


18.Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma


19.STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma


20.TNF-like ligand 1A is associated with progression and prognosis of human gastric cancer

最后,友情提醒大家,生信分析只是一个工具,不一定R语言或者是Python分析出来的就一定厉害,毕竟CNS都有一些文章还用DAVIDMetacape。因此,最主要的还是你的科学假设的新颖性,并且分析和实验共同论证了你的科学假设。

(0)

相关推荐